RGNX Seeks FDA Approval
REGENXBIO plans to resubmit its one-time gene therapy for Hunter Syndrome to the FDA after a path forward was established.
REGENXBIO Says FDA Path Opens for Hunter Syndrome Gene Therapy, Plans Quick FDA Resubmission for One-Time Rare Disease Treatment